43542 Federal Register / Vol. 82, No. 179 / Monday, September 18, 2017 / Notices 

drawn, as in the past, in large measure 

from the ranks of other executive branch 

agencies. The board shall review and 

evaluate the initial appraisal of each 

OGE senior executive’s performance by 

his or her supervisor, along with any 

recommendations in each instance to 

the appointing authority relative to the 

performance of the senior executive. 

This notice updates the membership of 

OGE’s SES Performance Review Board 

as it was most recently published at 78 

FR 76148 (December 16, 2013). 

Approved: September 13, 2017. 

David J. Apol, 

Acting Director, U.S. Office of Government 

Ethics. 

The following officials have been 

appointed members of the SES 

Performance Review Board of the Office 

of Government Ethics: Shelley K. 

Finlayson, [Chair], Chief of Staff and 

Program Counsel, Office of Government 

Ethics; Stuart Bender, Director, Office of 

Ethics, U.S. Department of Agriculture; 

Judith S. Kaleta, Deputy General 

Counsel, U.S. Department of 

Transportation; and Shira Pavis Minton, 

Ethics Counsel, Office of the Ethics 

Counsel, Securities and Exchange 

Commission. 

[FR Doc. 2017–19835 Filed 9–15–17; 8:45 am] 

BILLING CODE 6345–03–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–17–0888] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) has submitted the 

following information collection request 

to the Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. The notice for 

the proposed information collection is 

published to obtain comments from the 

public and affected agencies. 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information are encouraged. Your 

comments should address any of the 

following: (a) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (b) Evaluate the 

accuracy of the agencies estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; (d) Minimize the burden of 

the collection of information on those 

who are to respond, including through 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and (e) Assess information 

collection costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570 or 

send an email to omb@cdc.gov. Within 

30 days of this notice, direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC 20503 or by fax to (202) 395–5806. 

Proposed Project 

Factors Influencing the Transmission 

of Influenza (OMB Control Number 

0920–0888; Expired 6–30–2017)— 

Reinstatement with change—National 

Institute for Occupational Safety and 

Health (NIOSH), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

The National Institute for 

Occupational Safety and Health 

(NIOSH) is authorized to conduct 

research to advance the health and 

safety of workers under Section 20(a)(1) 

of the 1970 Occupational Safety and 

Health Act. Influenza continues to be a 

major public health concern because of 

the substantial health burden from 

seasonal influenza and the potential for 

a severe pandemic. Although influenza 

is known to be transmitted by infectious 

secretions, these secretions can be 

transferred from person to person in 

many different ways, and the relative 

importance of the different pathways is 

not known. The likelihood of the 

transmission of influenza virus by small 

infectious airborne particles produced 

during coughing and breathing is 

particularly unclear. The question of 

airborne transmission is especially 

important in healthcare facilities, where 

influenza patients tend to congregate 

during influenza season, because it 

directly impacts the infection control 

and personal protective measures that 

should be taken by healthcare workers. 

Work under the previous approval 

showed that patients infected with 

influenza virus produce airborne 

particles containing viable airborne 

influenza virus during both breathing 

and coughing, but that breathing may 

generate more airborne infectious 

material than coughing over time. 

However, this work was hampered 

because the amounts of influenza virus 

in almost all of the aerosol samples were 

below the limit of quantification. Thus, 

CDC made the following changes to the 

project: 

(1) CDC will modify the cough and 

exhalation-aerosol collection system to 

collect aerosol particles continuously 

for 40 minutes, rather than collecting 

particles from discrete coughs and 

exhalations as in the previous study. 

This will increase the amount of 

influenza virus that is collected. 

(2) Researchers will collect a blood 

sample from each participant to allow 

testing for blood markers of influenza 

infection and a comparison of the levels 

of these markers to the amount of 

expelled influenza in aerosol particles. 

(3) Researchers increased the time 

required for participation from 63 

minutes to 95 minutes to allow for a 

longer aerosol collection period and for 

the blood collection. 

(4) Researchers will recruit and test an 

equal number of control subjects 

without symptoms of respiratory illness 

in addition to subjects with influenzalike illness. This will allow the 

determination of the differences in 

blood biomarker levels between healthy 

and infected subjects. 

(5) Because of the longer participation 

time and because blood collection has 

been found to be a strong disincentive 

for participation, the token of 

appreciation for participating in the 

study has been increased from $25 to 

$40. 

The purpose of the proposed study is 

to gain a better understanding of the 

production of infectious aerosols by 

patients with influenza, and to compare 

this to the levels of biomarkers of 

influenza infection in the blood of these 

patients. To do this, researchers will 

collect airborne particles produced by 

volunteer subjects with influenza to test 

for influenza virus. Researchers will 

also measure the levels of influenza 

infection-associated biomarkers in blood 

samples from these subjects. 

A test coordinator will recruit 

volunteer adult participants by using a 

poster and flyers describing the study. 

Researchers will verbally screen 

interested potential participants to 

verify that they have influenza-like 

symptoms and that they do not have any 

medical conditions that would preclude 

their participation. Researchers will also 

recruit a matching number of healthy 

control participants. 

Researchers will ask qualified 

participants who agree to participate in 


sradovich on DSKBBY8HB2PROD with NOTICES
Federal Register / Vol. 82, No. 179 / Monday, September 18, 2017 / Notices 43543 

the study to read and sign an informed 

consent form, and then to complete a 

short health questionnaire. After 

completing the forms, researchers will 

measure the participant’s oral 

temperature and collect two 

nasopharyngeal mucus samples and five 

ml of blood. The researchers will then 

ask the participants to don elastomeric 

masks, and breathe and cough normally 

for 40 minutes into an aerosol particle 

collection system. The total time from 

initial verbal screening to completion 

will be about 95 minutes. 

The study will require 90 volunteer 

test subjects each year for 3 years, 

totaling 270 test participants. There are 

no costs to respondents other than their 

time. The total number of annual 

burden hours are 148. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hrs.) 

Potential participant ........................................ Initial verbal screening ................................... 180 1 3/60 

Qualified participant ........................................ Informed consent form ................................... 90 1 15/60

Qualified participant ........................................ Health questionnaire ...................................... 90 1 5/60 

Qualified participant ........................................ Medical testing ............................................... 90 1 72/60 

Leroy Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2017–19748 Filed 9–15–17; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Clinical Laboratory Improvement 

Advisory Committee (CLIAC) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), announces the 

following meeting for the Clinical 

Laboratory Improvement Advisory 

Committee (CLIAC). This meeting is 

open to the public, limited only by the 

space available. The meeting room 

accommodates approximately 100 

people. The public is also welcome to 

view the meeting by webcast http://

cdclabtraining.adobeconnect.com/cliac. 

DATES: The meeting will be held on 

November 1, 2017, 8:30 a.m. to 5:00 

p.m., EDT and November 2, 2017, 8:30 

a.m. to 12:00 p.m., EDT. 

ADDRESSES: CDC, 2500 Century Center 

Boulevard, Rooms 1200/1201, Atlanta, 

Georgia 30345 and http://cdclab

training.adobeconnect.com/cliac. 

FOR FURTHER INFORMATION CONTACT: 

Nancy Anderson, MMSc, MT(ASCP), 

Chief, Laboratory Practice Standards 

Branch, Division of Laboratory Systems, 

Center for Surveillance, Epidemiology 

and Laboratory Services, Office of 

Public Health Scientific Services, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE., 

Mailstop F–11, Atlanta, Georgia 30329– 

4018, telephone (404) 498–2741; 

NAnderson@cdc.gov. 

SUPPLEMENTARY INFORMATION: Purpose: 

This Committee is charged with 

providing scientific and technical 

advice and guidance to the Secretary of 

Health and Human Services (HHS); the 

Assistant Secretary for Health; the 

Director, Centers for Disease Control 

and Prevention; the Commissioner, 

Food and Drug Administration (FDA); 

and the Administrator, Centers for 

Medicare and Medicaid Services (CMS). 

The advice and guidance pertain to 

general issues related to improvement in 

clinical laboratory quality and 

laboratory medicine practice and 

specific questions related to possible 

revision of the Clinical Laboratory 

Improvement Amendment (CLIA) 

standards. Examples include providing 

guidance on studies designed to 

improve safety, effectiveness, efficiency, 

timeliness, equity, and patientcenteredness of laboratory services; 

revisions to the standards under which 

clinical laboratories are regulated; the 

impact of proposed revisions to the 

standards on medical and laboratory 

practice; and the modification of the 

standards and provision of nonregulatory guidelines to accommodate 

technological advances, such as new 

test methods, the electronic 

transmission of laboratory information, 

and mechanisms to improve the 

integration of public health and clinical 

laboratory practices. 

Matters To Be Considered: The agenda 

will include agency updates from CDC, 

Centers for Medicare and Medicaid 

Services (CMS), and The Food and Drug 

Administration (FDA). Presentations 

and discussions will focus on laboratory 

testing in the era of telemedicine; 

antibiotic resistance testing issues; 

culture independent diagnostic tests; 

and a report from the Institute of 

Medicine (IOM) CLIAC workgroup. 

Agenda items are subject to change as 

priorities dictate. 

All people attending the CLIAC 

meeting in-person are required to 

register for the meeting online at least 5 

business days in advance for U.S. 

citizens and at least 30 business days in 

advance for international registrants. 

Register at: https://wwwn.cdc.gov/ 

cliac/. Register by scrolling down and 

clicking the ‘‘Register for this Meeting’’ 

button and completing all forms 

according to the instructions given. 

Please complete all the required fields 

before submitting your registration and 

submit no later than October 25, 2017 

for U.S. registrants and September 19, 

2017 for international registrants. 

It is the policy of CLIAC to accept 

written public comments and provide a 

brief period for oral public comments on 

agenda items. Public comment periods 

for each agenda item are scheduled 

immediately prior to the Committee 

discussion period for that item. In 

general, each individual or group 

requesting to make oral comments will 

be limited to a total time of five minutes 

(unless otherwise indicated). To assure 

adequate time is scheduled for public 

comments, speakers should notify the 

contact person below at least one week 

prior to the meeting date. For 

individuals or groups unable to attend 

the meeting, CLIAC accepts written 

comments until the date of the meeting 

(unless otherwise stated). However, it is 

requested that comments be submitted 

at least one week prior to the meeting 

date so that the comments may be made 

available to the Committee for their 

consideration and public distribution. 


sradovich on DSKBBY8HB2PROD with NOTICES